Skip to main content

Table2 Integrins function as CSC markers in different solid cancers

From: Integrins regulate stemness in solid tumor: an emerging therapeutic target

Integrin subtype Cancer type Functions References
β4 TNBC Identifies a CSC-enriched population with partial mesenchymal traits [78]
  PDAC High level of β4 expression significantly correlates with stemness and EMT [79]
  Prostate Sustains the self-renewal of putative CSCs and promotes tumorigenesis by amplifying ErbB2 and c-Met signaling in tumor progenitor cells [80]
α6 Glioblastoma Co-expresses with conventional glioblastoma CSC markers and enriched for CSCs [54]
α7 OSCC Identifies a CSC-enriched population with elevated expression of SC genes and EMT features. The α7 co-expresses with the traditional CSC marker CD90 but further stratifies and marks a more tumorigenic subset [56]
β3 Breast A luminal epithelial progenitor marker that identifies a CSC population in mouse models of mammary tumorigenesis [81]
β8 Glioblastoma Overexpresses in and maintains glioblastoma CSC, and its overexpression induces radio-resistance and is correlated with poor prognosis [82]
αvβ3 Breast Regulates adult mammary SCs during pregnancy, and activates Slug in BCa cells to increase CSC features such as tumorsphere formation and tumor initiation [83]
α6 and β3 Breast α6highβ3high identifies a CSC-enriched population with enhanced tumorsphere formation and drug resistance to pacitaxel and doxorubicin in mouse Her2/neu transgenic breast tumors [55]
α2β1 NSCLC Exosomes derived from NSCLC cells carrying low levels of miR-34c-3p induce upregulation of α2β1, which promotes cancer cell invasion and migration [84]
  Colon Enhances metastatic capability and stemness of colorectal cancer cells via PI3K/AKT/Snail axis [85]
β1 HNSCC Promotes stemness, chemoresistance and tumor-forming capacity of cancer cells [86]
  OSCC Overexpresses in stem-like cancer cells and enhances cell proliferation, migration and tumorsphere formation [87]
  1. CSC cancer stem cells, TNBC triple-negative breast cancer, PDAC pancreatic ductal adenocarcinoma, OSCC oral squamous cell carcinoma, NSCLC Non-small-cell lung cancer, HNSCC head and neck squamous cell carcinoma, EMT epithelial-mesenchymal transition